Five Prime Therapeutics (FPRX) Poses Smaller Q4 Loss

Five Prime Therapeutics (NASDAQ: FPRX) reported Q4 EPS of ($1.12), $0.20 better than the analyst estimate of ($1.32). Revenue for the quarter came in at $4 million versus the consensus estimate of $8.01 million.

Cash, cash equivalents and marketable securities totaled $270.1 million as of December 31, 2018, compared to $292.7 million as of December 31, 2017. The decrease was primarily attributable to cash used in operating activities which was offset in part by the $107.6 million in net proceeds from the public offering of Five Prime’s common stock in January 2018.

“2018 was a year of significant expansion of our clinical pipeline,” said Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics. “Thanks to strong execution across our research, preclinical and clinical organizations, along with the contributions of the entire Five Prime team, we are positioned for a year of multiple data readouts. We began 2019 in a strong position with five assets in clinical development as well as the capital and support from our collaborators required to achieve our goals. By the end of 2019, we expect the bema FIGHT Phase 3 to be enrolling across nearly 200 sites globally and to disclose data from FPA150 and FPT155 that will inform the clinical path forward for these first-in-class programs. In addition, we are pleased with the continued progress of our BMS-partnered cabira and TIM-3 programs."

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c